Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil Zacks Investment Research - Fri Mar 14, 8:08AM CDT

Allogene Therapeutics ALLO incurred a loss of 28 cents per share in fourth-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents. In the year-ago period, the company had incurred...

ALLO : 1.6900 (-8.65%)
CTMX : 0.6037 (-4.61%)
ETNB : 8.55 (-1.72%)
ANIP : 64.22 (-0.20%)
Allogene Therapeutics: Q4 Earnings Snapshot AP - Thu Mar 13, 4:05PM CDT

Allogene Therapeutics: Q4 Earnings Snapshot

ALLO : 1.6900 (-8.65%)
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update GlobeNewswire - Thu Mar 13, 3:02PM CDT

ALLO : 1.6900 (-8.65%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 BayStreet.ca - Fri Mar 7, 8:20AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.6900 (-8.65%)
ONCY : 0.6067 (-3.01%)
TARA : 4.33 (-2.04%)
YMAB : 4.54 (-4.62%)
FATE : 0.9205 (-4.74%)
ONC.TO : 0.87 (-2.25%)
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update GlobeNewswire - Mon Mar 3, 7:30AM CST

ALLO : 1.6900 (-8.65%)
Allogene Therapeutics Announces Participation in March Investor Conference GlobeNewswire - Wed Feb 26, 7:30AM CST

ALLO : 1.6900 (-8.65%)
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia GlobeNewswire - Tue Feb 25, 3:10PM CST

ALLO : 1.6900 (-8.65%)
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise Stocktwits - Sun Feb 23, 11:22PM CST

Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy.

ALLO : 1.6900 (-8.65%)
PFE : 26.31 (+1.00%)
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins FinancialNewsMedia - Tue Feb 18, 10:24AM CST

Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause...

ONCY : 0.6067 (-3.01%)
ALLO : 1.6900 (-8.65%)
VRCA : 0.6500 (-0.08%)
ONC.TO : 0.87 (-2.25%)
OSTX : 1.6000 (-1.84%)
IBRX : 2.81 (-3.44%)
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins BayStreet.ca - Tue Feb 18, 8:05AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers),...

ALLO : 1.6900 (-8.65%)
ONCY : 0.6067 (-3.01%)
VRCA : 0.6500 (-0.08%)
ONC.TO : 0.87 (-2.25%)
IBRX : 2.81 (-3.44%)
OSTX : 1.6000 (-1.84%)

Barchart Exclusives

Want Over 8% Yield? 1 ‘Strong Buy’ Stock to Consider Now. Barchart - Tue Mar 18, 6:30PM CDT
This stock has paid dividends since 1976 and has a “Strong Buy” consensus rating. Moreover, it offers a high yield of 8.11%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot